PTGX FY 2018 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+54.1% YoY

Gross Profit

$31M100.0% margin

Operating Income

-$42M-136.7% margin

Net Income

-$39M-125.9% margin

EPS (Diluted)

$-1.74

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$139M

Total Liabilities

$27M

Stockholders' Equity

-$140M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$20M	+54.1%
Gross Profit	$31M	$20M	+54.1%
Operating Income	-$42M	-$38M	-11.5%
Net Income	-$39M	-$37M	-5.3%